Autolus Therapeutics Ltd (AUTL) ADS Each Rep 1 Ord Shs

Sell:$2.13Buy:$2.14$0.06 (2.73%)

NASDAQ:0.51%
Market closed | Prices delayed by at least 15 minutes
Sell:$2.13
Buy:$2.14
Change:$0.06 (2.73%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$2.13
Buy:$2.14
Change:$0.06 (2.73%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Key people

Michael W. Bonney
Chairman of the Board
Christian Martin Itin
Chief Executive Officer, Executive Director
Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Lucinda Crabtree
Chief Financial Officer, Senior Vice President
Christopher Vann
Chief Operating Officer, Senior Vice President
Edgar Braendle
Senior Vice President
David Brochu
Senior Vice President, Chief Technical Officer
Brent Rice
Senior Vice President, Chief Commercial Officer
Matthias Will
Chief Development Officer
Robert W. Azelby
Director
Elisabeth Leiderman
Director
Ravi M. Rao
Director
Joseph Anderson
Non-Executive Independent Director
Linda C. Bain
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US05280R1005
  • Market cap
    $601.44m
  • Employees
    463
  • Shares in issue
    266.09m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.